| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
American Prosthetics and Orthotics is a Clive, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Serving markets in the US and Canada, Vision Group Holdings oversees and manages the leading LASIK and laser eye surgery providers in North America.
UC San Diego Health Sciences has long been known as a place where discoveries are made. Today, we are known as a place where discoveries are delivered. UC San Diego Health Sciences encompasses the School of Medicine, the Skaggs School of Pharmacy and Pharmaceutical Sciences, and UC San Diego Health System, including UC San Diego Medical Center, in Hillcrest; and in La Jolla, Thornton Hospital, Moores Cancer Center, Sulpizio Cardiovascular Center; and other centers, primary and specialty practices of the UC San Diego Medical Group faculty physicians. As a top-tier academic medical center, its role is to provide leadership in improving health through research, education and patient care. UC San Diego Health Sciences has long been at the forefront of “bench-to-bedside” research, transforming patient care through discovery and innovation leading to new drugs and technologies. It is carried out every day in the hundreds of clinical trials of promising new therapies offered through UC San Diego Health System, and in the drive of our researchers and clinician-scientists who are committed to having a significant impact on patient care. At UC San Diego Health Sciences, there are many discoveries on our horizon. Our commitment is to continue our quest to cure disease, seek better treatments and train the next generation of physicians and scientists.
Angels Harbor is a residential treatment facility located in Vincent, Ohio that offers inpatient residential treatment services to women struggling with substance use.